We are focused on utilizing 3D culture technology to develop drugs across a range of therapeutic areas. Founded by a combination of former Organovo and Ardea Biosciences scientists and entrepreneurs, Viscient is initially conducting discovery and development work in non-alcoholic fatty liver disease (“NAFLD”) and non-alcoholic steatohepatitis (“NASH”). Utilizing newly available three dimensional biology technologies, we explore biology in a previously unavailable context, leading to a better understanding of disease and an improved opportunity to impact patients.